Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Gastric cancer is commonly diagnosed at an advanced stage when metastasis is almost inevitable. Despite numerous novel regulators have been identified in driving gastric cancer progression, much remains unclear due to the complex nature of cancer. Comparison of the transcriptome profiles of gastric primary tumor tissue, with its matched non-tumor and lymph node metastasis revealed frequent stepwise down-regulation of
sclerostin domain containing 1
(
SOSTDC1
) related with tumor progression. Clinically, deficiency of this gene is associated with shortened survival of patients. Our results suggest that
SOSTDC1
confers tumor-suppressive features in gastric cancer and silencing of it accelerates tumor growth and promotes the formation of lung metastasis. Although
SOSTDC1
displayed limited inhibition of canonical SMAD-dependent bone morphogenetic proteins (BMP) pathway, it remarkably restrained the
c-Jun
activation and transcription of
c-Jun
downstream targets in the noncanonical BMP signaling pathway. Furthermore, c-Jun N-terminal kinase (JNK) blockage attenuated cell proliferative and migrative advantages of
SOSTDC1
knockdown cell lines. Our study comprehensively elucidated the role of
SOSTDC1
in gastric cancer progression and the results translate into potential therapy for gastric cancer.
...
PMID:The BMP antagonist, SOSTDC1, restrains gastric cancer progression via inactivation of c-Jun signaling. 3181 38
